{"nctId":"NCT03095456","briefTitle":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","startDateStruct":{"date":"2017-03-27","type":"ACTUAL"},"conditions":["Chronic Obstructive Pulmonary Disease, COPD","Low Peak Inspiratory Flow Rate (PIFR)"],"count":207,"armGroups":[{"label":"Revefenacin","type":"EXPERIMENTAL","interventionNames":["Drug: Revefenacin","Drug: Placebo for Spiriva Handihaler®"]},{"label":"Spiriva Handihaler®","type":"ACTIVE_COMPARATOR","interventionNames":["Combination Product: Spiriva Handihaler®","Drug: Placebo for Revefenacin"]}],"interventions":[{"name":"Revefenacin","otherNames":["TD-4208"]},{"name":"Spiriva Handihaler®","otherNames":["Tiotropium"]},{"name":"Placebo for Revefenacin","otherNames":[]},{"name":"Placebo for Spiriva Handihaler®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is a male or female subject 40 years of age or older with a diagnosis of COPD.\n* Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years.\n* Subject is willing and able to provide signed and dated written informed consent to participate prior to initiation of any study related procedures.\n\nExclusion Criteria:\n\n* Subject has a concurrent disease or condition that, in the opinion of the investigator, would interfere with continued study participation or confound the evaluation of safety and tolerability of the study drug.\n* Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics.\n* Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Trough FEV1 on Day 29","description":"FEV1 = forced expiratory volume at one second","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":"20.17"},{"groupId":"OG001","value":"47.3","spread":"19.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Trough FVC (Forced Vital Capacity) on Day 29","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.4","spread":"38.75"},{"groupId":"OG001","value":"55.8","spread":"36.62"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Trough Inspiratory Capacity (IC) on Day 29","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":"42.33"},{"groupId":"OG001","value":"84.1","spread":"40.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Peak FEV1 on Day 29","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174.2","spread":"18.70"},{"groupId":"OG001","value":"197.7","spread":"17.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Peak FVC on Day 29","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"354.2","spread":"37.35"},{"groupId":"OG001","value":"340.1","spread":"35.49"}]}]}]},{"type":"SECONDARY","title":"Summary of Rescue Medication Use: Puffs Per Day","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.42"},{"groupId":"OG001","value":"2.9","spread":"0.41"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":103},"commonTop":["Headache","Dyspnoea","Oropharyngeal pain","Constipation","Cough"]}}}